Egyptian International Pharmaceutical Industries Company (EGX:PHAR)
Egypt · Delayed Price · Currency is EGP 119.00
-6.11 (-4.88%)
At close: Sep 14, 2026
EGX:PHAR Ratios and Metrics
Market cap in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 20,082 | 13,079 | 6,829 | 5,430 | 3,621 | 4,155 | |
Market Cap Growth | 93.65% | 91.51% | 25.78% | 49.96% | -12.86% | -3.57% |
Enterprise Value | 29,928 | 21,426 | 14,578 | 9,630 | 5,388 | 5,509 |
Last Close Price | 119.00 | 74.36 | 41.42 | 31.36 | 22.75 | 24.04 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 15.56 | 9.07 | 6.23 | 6.60 | 5.63 | 8.52 |
Forward PE | 18.48 | 9.34 | 7.03 | 5.92 | 5.77 | 6.23 |
PS Ratio | 2.03 | 1.39 | 0.90 | 1.04 | 0.92 | 1.22 |
PB Ratio | 3.30 | 2.00 | 1.47 | 1.27 | 1.12 | 1.40 |
P/TBV Ratio | 3.32 | 2.11 | 1.48 | 1.28 | 1.12 | 1.40 |
P/OCF Ratio | - | 11.96 | - | 58.71 | - | 10.83 |
PEG Ratio | - | 0.52 | 0.52 | 0.37 | 0.36 | 0.42 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.03 | 2.27 | 1.92 | 1.84 | 1.36 | 1.62 |
EV/EBITDA Ratio | 10.79 | 8.74 | 9.07 | 7.33 | 7.10 | 6.35 |
EV/EBIT Ratio | 11.60 | 9.15 | 9.67 | 7.95 | 8.14 | 7.09 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.65 | 1.35 | 1.98 | 1.15 | 0.88 | 0.59 |
Debt / EBITDA Ratio | 4.42 | 3.59 | 5.73 | 3.74 | 3.76 | 2.03 |
Net Debt / Equity Ratio | 1.62 | 1.13 | 1.70 | 1.00 | 0.73 | 0.49 |
Net Debt / EBITDA Ratio | 4.33 | 3.01 | 4.93 | 3.23 | 3.13 | 1.67 |
Net Debt / FCF Ratio | -6.68 | -28.25 | -1.92 | -1.93 | -2.77 | -27.25 |
Asset Turnover | 0.55 | 0.56 | 0.60 | 0.63 | 0.66 | 0.66 |
Inventory Turnover | 1.41 | 1.42 | 1.46 | 1.36 | 1.21 | 1.08 |
Quick Ratio | 0.28 | 0.39 | 0.36 | 0.65 | 0.54 | 0.67 |
Current Ratio | 0.97 | 1.16 | 1.12 | 1.94 | 1.72 | 2.13 |
Return on Equity (ROE) | 20.51% | 26.06% | 24.60% | 21.95% | 20.71% | 16.78% |
Return on Assets (ROA) | 7.24% | 8.70% | 7.43% | 9.04% | 6.89% | 9.46% |
Return on Invested Capital (ROIC) | 11.31% | 14.54% | 10.39% | 13.21% | 10.69% | 14.11% |
Return on Capital Employed (ROCE) | 21.70% | 22.30% | 18.50% | 16.90% | 16.10% | 21.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.18% | 11.02% | 16.04% | 15.14% | 17.76% | 11.74% |
FCF Yield | -7.33% | -2.00% | -60.34% | -40.48% | -23.75% | -1.28% |
Dividend Yield | 1.16% | - | 3.62% | 3.19% | 4.40% | 6.24% |
Payout Ratio | 49.46% | 42.41% | 39.61% | 37.67% | 61.14% | 78.64% |
Buyback Yield / Dilution | -2.17% | -8.91% | - | -50.00% | - | -1.64% |
Total Shareholder Return | -1.01% | -8.91% | 3.62% | -46.81% | 4.40% | 4.60% |